![](/img/cover-not-exists.png)
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
Michl, M., Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmueller, C., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., SLanguage:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw222
Date:
May, 2016
File:
PDF, 1.11 MB
english, 2016